This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Among patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, neoadjuvant FOLFIRINOX showed comparable overall survival to neoadjuvant gemcitabine-based chemoradiotherapy, ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

SAN DIEGO and CALGARY, AB, Jan. 22, 2025 /PRNewswire/ -- Oncolytics Biotech (ONCY) ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...

Please provide your email address to receive an email when new articles are posted on . The addition of modified FOLFIRINOX induction chemotherapy to standard care improved metastasis-free survival.

MELBOURNE, Australia, May 29, 2023 /PRNewswire/ -- Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK ...

On October 3, 2025, a multicenter team from Shenzhen University, Xiangya Hospital of Central South University, Zhujiang Hospital of Southern Medical University, Wuxi People's Hospital Affiliated to ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to ...